Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of IL-2/IFN-α Plus Bevacizumab Versus IL-2/IFN-α in Metastatic Renal Cell Carcinoma (mRCC) - Danish Renal Cancer Group (DARENCA) Study-1

NCT01274273 is registered in ClinicalTrials.gov with University of Aarhus as lead sponsor.

NCT NCT01274273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01274273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of IL-2/IFN-α Plus Bevacizumab Versus IL-2/IFN-α in Metastatic Renal Cell Carcinoma (mRCC) - Danish Renal Cancer Group (DARENCA) Study-1
Lead sponsor
University of Aarhus
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2009
Completion date
December 31, 2015
Enrollment
118 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma